<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOCETIRIZINE DIHYDROCHLORIDE- levocetirizine dihydrochloride solution </strong><br>Taro Pharmaceuticals U.S.A., inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LEVOCETIRIZINE Dihydrochloride Oral Solution safely and effectively. See full prescribing information for LEVOCETIRIZINE Dihydrochloride Oral Solution.<br> LEVOCETIRIZINE Dihydrochloride Oral Solution<br> 2.5 mg/5 mL (0.5 mg/mL)<br> Initial U.S. Approval: 1995</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL (0.5 mg/mL) is a histamine H<span class="Sub">1</span>-receptor antagonist indicated for: </p>
<ul class="Disc">
<li>The relief of symptoms associated with seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> (<a href="#S1.1">1.1</a>, <a href="#S1.2">1.2</a>)</li>
<li>The treatment of the uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> (<a href="#S1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Adults and children 12 years of age and older: 5 mg once daily in the evening (<a href="#S2.1">2.1</a>)</li>
<li>Children 6 to 11 years of age: 2.5 mg once daily in the evening (<a href="#S2.2">2.2</a>)</li>
<li>Children 6 months to 5 years of age: 1.25 mg (½ teaspoon oral solution) [2.5mL] once daily in the evening (<a href="#S2.3">2.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br> Adjust the dose in patients 12 years of age and older with decreased renal function (<a href="#S2.4">2.4</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Immediate release oral solution, 2.5 mg per 5 mL (0.5 mg per mL) (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levocetirizine or any of the ingredients of levocetirizine dihydrochloride oral solution, 2.5 mg/5 mL (0.5 mg/mL) or to cetirizine (<a href="#S4.1">4.1</a>)</li>
<li>Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis (<a href="#S4.2">4.2</a>)</li>
<li>Children 6 months to 11 years of age with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#S4.3">4.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking levocetirizine dihydrochloride (<a href="#S5.1">5.1</a>).</li>
<li>Avoid concurrent use of alcohol or other central nervous system depressants with levocetirizine dihydrochloride (<a href="#S5.1">5.1</a>).</li>
<li>Use with caution in patients with predisposing factors of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (e.g. spinal cord lesion, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hyperplasia</span>). Discontinue levocetirizine dihydrochloride if <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> occurs (<a href="#S5.2">5.2</a>).</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (rate ≥2% and &gt; placebo) were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> in subjects 12 years of age and older, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> in children 6 to 12 years of age. In subjects 1 to 5 years of age, the most common adverse reactions (rate ≥2% and &gt; placebo) were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. In subjects 6 to 11 months of age, the most common adverse reactions (rate ≥3% and &gt; placebo) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Taro Pharmaceuticals U.S.A., Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br> Because levocetirizine dihydrochloride is substantially excreted by the kidneys, the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (<a href="#S8.6">8.6</a> and <a href="#S12.3">12.3</a>).</li>
<li>Pediatric Use<br> Do not exceed the recommended doses of 2.5 mg and 1.25 mg once daily in children 6 to 11 years and 6 months to 5 years of age, respectively. Systemic exposure with these doses in respective pediatric age groups is comparable to that from a 5 mg once daily dose in adults. (<a href="#S12.3">12.3</a>).</li>
</ul></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults and Children 12 Years of Age and Older</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Children 6 to 11 Years of Age</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Children 6 months to 5 Years of Age</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Adjustment for Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Ritonavir</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Concomitant Use of Alcohol and other Central Nervous System Depressants</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Dosing of Levocetirizine dihydrochloride oral solution</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></h2>
<p class="First">Levocetirizine dihydrochloride oral solution is indicated for the relief of symptoms associated with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in adults and children 2 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></h2>
<p class="First">Levocetirizine dihydrochloride oral solution is indicated for the relief of symptoms associated with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> in adults and children 6 months of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h2>
<p class="First">Levocetirizine dihydrochloride oral solution is indicated for the treatment of the uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in adults and children 6 months of age and older.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Levocetirizine dihydrochloride oral solution is available as 2.5 mg/5 mL (0.5 mg/mL) oral solution. Levocetirizine dihydrochloride can be taken without regard to food consumption.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults and Children 12 Years of Age and Older</h2>
<p class="First">The recommended dose of levocetirizine dihydrochloride is 5 mg (2 teaspoons [10 mL] oral solution) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (1 teaspoon [5 mL] oral solution) once daily in the evening.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Children 6 to 11 Years of Age</h2>
<p class="First">The recommended dose of levocetirizine dihydrochloride is 2.5 mg (1 teaspoon [5 mL] oral solution) once daily in the evening. The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Children 6 months to 5 Years of Age</h2>
<p class="First">The recommended initial dose of levocetirizine dihydrochloride is 1.25 mg (½ teaspoon oral solution) [2.5 mL] once daily in the evening. The 1.25 mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5 mg [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Adjustment for Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In adults and children 12 years of age and older with:</p>
<ul class="Disc">
<li>Mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CL<span class="Sub">CR</span>] = 50 to 80 mL/min): a dose of 2.5 mg once daily is recommended;</li>
<li>Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> = 30 to 50 mL/min): a dose of 2.5 mg once every other day is recommended;</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> = 10 to 30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3 to 4 days) is recommended;</li>
<li>End-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients (CL<span class="Sub">CR</span> &lt; 10 mL/min) and patients undergoing hemodialysis should not receive levocetirizine dihydrochloride.</li>
</ul>
<p>No dose adjustment is needed in patients with solely <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In patients with both <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, adjustment of the dose is recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Levocetirizine dihydrochloride oral solution is a clear, colorless, tutti frutti flavored liquid containing 0.5 mg of levocetirizine dihydrochloride per mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">The use of levocetirizine dihydrochloride is contraindicated in:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></h2>
<p class="First">Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levocetirizine or any of the ingredients of levocetirizine dihydrochloride, or to cetirizine. Observed reactions range from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></h2>
<p class="First">Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (CL<span class="Sub">CR</span> &lt; 10 mL/min) and patients undergoing hemodialysis</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span></h2>
<p class="First">Children 6 months to 11 years of age with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">In clinical trials the occurrence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> has been reported in some patients under therapy with levocetirizine dihydrochloride. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness, and motor coordination such as operating machinery or driving a motor vehicle after ingestion of levocetirizine dihydrochloride. Concurrent use of levocetirizine dihydrochloride with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> has been reported post-marketing with levocetirizine dihydrochloride. Levocetirizine dihydrochloride should be used with caution in patients with predisposing factors of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (e.g. spinal cord lesion, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hyperplasia</span>) as levocetirizine dihydrochloride may increase the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Discontinue levocetirizine dihydrochloride if <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> occurs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Use of levocetirizine dihydrochloride has been associated with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> [see <span class="Italics"><a href="#S5">Warnings and Precautions (5)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">The safety data described below reflect exposure to levocetirizine dihydrochloride in 2708 patients with seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> or chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in 14 controlled clinical trials of 1 week to 6 months duration.</p>
<p>The short-term (exposure up to 6 weeks) safety data for adults and adolescents are based upon eight clinical trials in which 1896 patients (825 males and 1071 females aged 12 years and older) were treated with levocetirizine dihydrochloride 2.5, 5, or 10 mg once daily in the evening. The short-term safety data from pediatric patients are based upon two clinical trials in which 243 children with seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> (162 males and 81 females 6 to 12 years of age) were treated with levocetirizine dihydrochloride 5 mg once daily for 4 to 6 weeks, one clinical trial in which 114 children (65 males and 49 females 1 to 5 years of age) with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> or chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> were treated with levocetirizine dihydrochloride 1.25 mg twice daily for 2 weeks, and one clinical trial in which 45 children (28 males and 17 females 6 to 11 months of age) with symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> or <span class="product-label-link" type="condition" conceptid="4198855" conceptname="Chronic urticaria">chronic urticaria</span> were treated with levocetirizine dihydrochloride 1.25 mg once daily for 2 weeks.</p>
<p>The long-term (exposure of 4 or 6 months) safety data in adults and adolescents are based upon two clinical trials in which 428 patients (190 males and 238 females) with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> were exposed to treatment with levocetirizine dihydrochloride 5 mg once daily. Long term safety data are also available from an 18-month trial in 255 levocetirizine dihydrochloride-treated subjects 12 to 24 months of age.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Adults and Adolescents 12 years of Age and Older</span></p>
<p>In studies up to 6 weeks in duration, the mean age of the adult and adolescent patients was 32 years, 44% of the patients were men and 56% were women, and the large majority (more than 90%) was Caucasian. In these trials 43% and 42% of the subjects in the levocetirizine dihydrochloride 2.5 mg and 5 mg groups, respectively, had at least one adverse event compared to 43% in the placebo group.</p>
<p>In placebo-controlled trials of 1 to 6 weeks in duration, the most common adverse reactions were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and most were mild to moderate in intensity. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> with levocetirizine dihydrochloride showed dose ordering between tested doses of 2.5, 5 and 10 mg and was the most common adverse reaction leading to discontinuation (0.5%).</p>
<p>Table 1 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 12 years and older exposed to levocetirizine dihydrochloride 2.5 mg or 5 mg in eight placebo-controlled clinical trials and that were more common with levocetirizine dihydrochloride than placebo.</p>
<a name="table1"></a><table width="90%">
<caption><span>Table 1 Adverse Reactions Reported in ≥ 2%<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> of Subjects Aged 12 Years and Older Exposed to Levocetirizine dihydrochloride 2.5 mg or 5 mg Once Daily in Placebo-Controlled Clinical Trials 1 to 6 Weeks in Duration</span></caption>
<col align="center" valign="middle" width="27%">
<col align="center" valign="middle" width="27%">
<col align="center" valign="middle" width="27%">
<col align="center" valign="middle" width="19%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Adverse Reactions</th>
<th class="Lrule" align="center">Levocetirizine dihydrochloride<br> 2.5 mg<br> (n = 421)</th>
<th class="Lrule" align="center">Levocetirizine dihydrochloride<br> 5 mg<br> (n = 1070)</th>
<th class="Lrule Rrule" align="center" valign="bottom">Placebo<br> (n = 912)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Rounded to the closest unit percentage</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule" align="center">22 (5%)</td>
<td class="Lrule" align="center">61 (6%)</td>
<td class="Lrule Rrule" align="center">16 (2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule" align="center">25 (6%)</td>
<td class="Lrule" align="center">40 (4%)</td>
<td class="Lrule Rrule" align="center">28 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">5 (1%)</td>
<td class="Lrule" align="center">46 (4%)</td>
<td class="Lrule Rrule" align="center">20 (2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Lrule" align="center">12 (3%)</td>
<td class="Lrule" align="center">26 (2%)</td>
<td class="Lrule Rrule" align="center">11 (1%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Lrule" align="center">10 (2%)</td>
<td class="Lrule" align="center">12 (1%)</td>
<td class="Lrule Rrule" align="center">9 (1%)</td>
</tr>
</tbody>
</table>
<p>Additional adverse reactions of medical significance observed at a higher incidence than in placebo in adults and adolescents aged 12 years and older exposed to levocetirizine dihydrochloride are <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (0.2%) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> (0.5%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients 6 to 12 Years of Age</span></p>
<p>A total of 243 pediatric patients 6 to 12 years of age received levocetirizine dihydrochloride 5 mg once daily in two short-term placebo controlled double-blind trials. The mean age of the patients was 9.8 years, 79 (32%) were 6 to 8 years of age, and 50% were Caucasian. Table 2 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 6 to 12 years exposed to levocetirizine dihydrochloride 5 mg in placebo-controlled clinical trials and that were more common with levocetirizine dihydrochloride than placebo.</p>
<table width="90%">
<caption><span>Table 2 Adverse Reactions Reported in ≥ 2%<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> of Subjects Aged 6 to 12 Years Exposed to Levocetirizine dihydrochloride 5 mg Once Daily in Placebo-Controlled Clinical Trials 4 and 6 Weeks in Duration</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Adverse Reactions</th>
<th class="Lrule" align="center">Levocetirizine dihydrochloride 5 mg<br> (n = 243)</th>
<th class="Lrule Rrule" align="center">Placebo<br> (n = 240)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Rounded to the closest unit percentage</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Lrule" align="center">10 (4%)</td>
<td class="Lrule Rrule" align="center">5 (2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Lrule" align="center">8 (3%)</td>
<td class="Lrule Rrule" align="center">2 (&lt;1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Lrule" align="center">7 (3%)</td>
<td class="Lrule Rrule" align="center">1 (&lt;1%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Lrule" align="center">6 (2%)</td>
<td class="Lrule Rrule" align="center">1 (&lt;1%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients 1 to 5 Years of Age</span></p>
<p>A total of 114 pediatric patients 1 to 5 years of age received levocetirizine dihydrochloride 1.25 mg twice daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 3.8 years, 32% were 1 to 2 years of age, 71% were Caucasian and 18% were Black. Table 3 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 1 to 5 years exposed to levocetirizine dihydrochloride 1.25 mg twice daily in the placebo-controlled safety trial and that were more common with levocetirizine dihydrochloride than placebo.</p>
<table width="90%">
<caption><span>Table 3 Adverse Reactions Reported in ≥ 2%<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> of Subjects Aged 1 to 5 Years Exposed to Levocetirizine dihydrochloride 1.25 mg Twice Daily in a 2-Week Placebo-Controlled Clinical Trial</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Adverse Reactions</th>
<th class="Lrule" align="center">Levocetirizine dihydrochloride<br> 1.25 mg Twice Daily<br>(n = 114)</th>
<th class="Lrule Rrule" align="center" valign="bottom">Placebo<br> (n = 59)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Rounded to the closest unit percentage</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Lrule" align="center">5 (4%)</td>
<td class="Lrule Rrule" align="center">1 (2%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">4 (4%)</td>
<td class="Lrule Rrule" align="center">2 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">4 (4%)</td>
<td class="Lrule Rrule" align="center">2 (3%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></td>
<td class="Lrule" align="center">3 (3%)</td>
<td class="Lrule Rrule" align="center">0 (0%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients 6 to 11 Months of Age</span></p>
<p>A total of 45 pediatric patients 6 to 11 months of age received levocetirizine dihydrochloride 1.25 mg once daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 9 months, 51% were Caucasian and 31% were Black. Adverse reactions that were reported in more than 1 subject (i.e. greater than or equal to 3% of subjects) aged 6 to 11 months exposed to levocetirizine dihydrochloride 1.25 mg once daily in the placebo-controlled safety trial and that were more common with levocetirizine dihydrochloride than placebo included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> which were reported in 6 (13%) and 1 (4%) and 3 (7%) and 1 (4%) children in the levocetirizine dihydrochloride and placebo-treated groups, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold Italics">Long-Term Clinical Trials Experience</span></p>
<p>In two controlled clinical trials, 428 patients (190 males and 238 females) aged 12 years and older were treated with levocetirizine dihydrochloride 5 mg once daily for 4 or 6 months. The patient characteristics and the safety profile were similar to that seen in the short-term studies. Ten (2.3%) patients treated with levocetirizine dihydrochloride discontinued because of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> compared to 2 (&lt; 1%) in the placebo group. There are no long term clinical trials in children below 12 years of age with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> or chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold Italics">Laboratory Test Abnormalities</span></p>
<p>Elevations of blood bilirubin and transaminases were reported in &lt;1% of patients in the clinical trials. The elevations were transient and did not lead to discontinuation in any patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">In addition to the adverse reactions reported during clinical trials and listed above, adverse events have also been identified during post-approval use of levocetirizine dihydrochloride. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse events of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorders</span> (including <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> and <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>), <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been reported.</p>
<p>Besides these events reported under treatment with levocetirizine dihydrochloride, other potentially severe adverse events have been reported from the post-marketing experience with cetirizine. Since levocetirizine is the principal pharmacologically active component of cetirizine, one should take into account the fact that the following adverse events could also potentially occur under treatment with levocetirizine dihydrochloride: <span class="product-label-link" type="condition" conceptid="376969" conceptname="Orofacial dyskinesia">orofacial dyskinesia</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, still birth, tic, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vitro</span> data indicate that levocetirizine is unlikely to produce <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> through inhibition or induction of liver drug-metabolizing enzymes. No <span class="Italics">in vivo</span> drug-drug interaction studies have been performed with levocetirizine. Drug interaction studies have been performed with racemic cetirizine.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interaction</span> studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole, and cimetidine. There was a small decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline. It is possible that higher theophylline doses could have a greater effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2 Ritonavir</h2>
<p class="First">Ritonavir increased the plasma AUC of cetirizine by about 42% accompanied by an increase in half-life (53%) and a decrease in clearance (29%) of cetirizine. The disposition of ritonavir was not altered by concomitant cetirizine administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, levocetirizine dihydrochloride should be used during pregnancy only if clearly needed.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects:</span></p>
<p>In rats and rabbits, levocetirizine was not teratogenic at oral doses approximately 320 and 390, respectively, times the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">No peri- and post-natal animal studies have been conducted with levocetirizine. In mice, cetirizine caused retarded pup <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during lactation at an oral dose in dams that was approximately 40 times the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis. Studies in beagle dogs indicated that approximately 3% of the dose of cetirizine was excreted in milk. Cetirizine has been reported to be excreted in human breast milk. Because levocetirizine is also expected to be excreted in human milk, use of levocetirizine dihydrochloride in nursing mothers is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The recommended dose of levocetirizine dihydrochloride for the treatment of the uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> in patients 6 months to 17 years of age is based on extrapolation of efficacy from adults 18 years of age and older [see <span class="Italics"><a href="#S14">Clinical Studies (14)</a></span>]. The recommended dose of levocetirizine dihydrochloride in patients 6 months to 11 years of age for the treatment of the symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> and chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> and in patients 2 to 11 years of age for the treatment of symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> is based on cross-study comparisons of the systemic exposure of levocetirizine dihydrochloride in adults and pediatric patients and on the safety profile of levocetirizine dihydrochloride in both adult and pediatric patients at doses equal to or higher than the recommended dose for patients 6 months to 11 years of age.</p>
<p>The safety of levocetirizine dihydrochloride 5 mg once daily was evaluated in 243 pediatric patients 6 to 12 years of age in two placebo-controlled clinical trials lasting 4 and 6 weeks. The safety of levocetirizine dihydrochloride 1.25 mg twice daily was evaluated in one 2-week clinical trial in 114 pediatric patients 1 to 5 years of age and the safety of levocetirizine dihydrochloride 1.25 mg once daily was evaluated in one 2-week clinical trial in 45 pediatric patients 6 to 11 months of age [see <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p>
<p>The effectiveness of levocetirizine dihydrochloride 1.25 mg once daily (6 months to 5 years of age) and 2.5 mg once daily (6 to 11 years of age) for the treatment of the symptoms of seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> and chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> is supported by the extrapolation of demonstrated efficacy of levocetirizine dihydrochloride 5 mg once daily in patients 12 years of age and older based on the pharmacokinetic comparison between adults and children.</p>
<p>Cross-study comparisons indicate that administration of a 5 mg dose of levocetirizine dihydrochloride to 6 to 12 year old pediatric <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> patients resulted in about 2-fold the systemic exposure (AUC) observed when 5 mg of levocetirizine dihydrochloride was administered to healthy adults. Therefore, in children 6 to 11 years of age the recommended dose of 2.5 mg once daily should not be exceeded. In a population pharmacokinetics study the administration of 1.25 mg once daily in children 6 months to 5 years of age resulted in systemic exposure comparable to 5 mg once daily in adults. [see <span class="Italics"><a href="#S2.2">Dosage and Administration (2.2)</a>; <a href="#S14">Clinical Studies (14)</a>;</span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of levocetirizine dihydrochloride for each approved indication did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Levocetirizine dihydrochloride is known to be substantially excreted by the kidneys and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">As levocetirizine is mainly excreted unchanged by the kidneys, it is unlikely that the clearance of levocetirizine is significantly decreased in patients with solely <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage has been reported with levocetirizine dihydrochloride.</p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in adults and initially <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in children. There is no known specific antidote to levocetirizine dihydrochloride. Should <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occur, symptomatic or supportive treatment is recommended. Levocetirizine dihydrochloride is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested.</p>
<p>The acute maximal non-lethal oral dose of levocetirizine was 240 mg/kg in mice (approximately 190 times the maximum recommended daily oral dose in adults, approximately 230 times the maximum recommended daily oral dose in children 6 to 11 years of age, and approximately 180 times the maximum recommended daily oral dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2</span> basis). In rats the maximal non-lethal oral dose was 240 mg/kg (approximately 390 times the maximum recommended daily oral dose in adults, approximately 460 times the maximum recommended daily oral dose in children 6 to 11 years of age, and approximately 370 times the maximum recommended daily oral dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride oral solution, is an orally active H<span class="Sub">1</span>-receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy] acetic acid dihydrochloride. Levocetirizine dihydrochloride is the R enantiomer of cetirizine hydrochloride, a racemic compound with antihistaminic properties. The empirical formula of levocetirizine dihydrochloride is C<span class="Sub">21</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">3</span>∙2HCl. The molecular weight is 461.82 and the chemical structure is shown below:</p>
<p>          <img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=df2a19c7-f437-425c-8253-a2523122a653&amp;name=levocetirizine-01.jpg"></p>
<p>Levocetirizine dihydrochloride is a white, crystalline powder and is water soluble. Levocetirizine dihydrochloride 0.5 mg/mL oral solution is formulated as an immediate release, clear, colorless liquid. Inactive ingredients are: glacial acetic acid, glycerin, maltitol solution, methylparaben, propylparaben, purified water, sodium acetate (anhydrous), sucralose, and tutti frutti flavor.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H<span class="Sub">1</span>-receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. <span class="Italics">In vitro</span> binding studies revealed that levocetirizine has an affinity for the human H<span class="Sub">1</span>-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L <span class="Italics">vs.</span> 6 nmol/L, respectively). The clinical relevance of this finding is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Studies in adult healthy subjects showed that levocetirizine at doses of 2.5 mg and 5 mg inhibited the skin wheal and flare caused by the intradermal injection of histamine. In contrast, dextrocetirizine exhibited no clear change in the inhibition of the wheal and flare reaction. Levocetirizine at a dose of 5 mg inhibited the wheal and flare caused by intradermal injection of histamine in 14 pediatric subjects (aged 6 to 11 years) and the activity persisted for at least 24 hours. The clinical relevance of histamine wheal skin testing is unknown.</p>
<p>A QT/QTc study using a single dose of 30 mg of levocetirizine did not demonstrate an effect on the QTc interval. While a single dose of levocetirizine had no effect, the effects of levocetirizine may not be at steady state following single dose. The effect of levocetirizine on the QTc interval following multiple dose administration is unknown. Levocetirizine is not expected to have QT/QTc effects because of the results of QTc studies with cetirizine and the long post-marketing history of cetirizine without reports of QT prolongation.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Levocetirizine exhibited linear pharmacokinetics over the therapeutic dose range in adult healthy subjects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">• Absorption</span></p>
<p>Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 hour after administration of the oral tablet. The accumulation ratio following daily oral administration is 1.12 with steady state achieved after 2 days. Peak concentrations are typically 270 ng/mL and 308 ng/mL following a single and a repeated 5 mg once daily dose, respectively. Food had no effect on the extent of exposure (AUC) of the levocetirizine tablet, but T<span class="Sub">max </span>was delayed by about 1.25 hours and C<span class="Sub">max</span> was decreased by about 36% after administration with a high fat meal; therefore, levocetirizine can be administered with or without food.</p>
<p>A dose of 5 mg (10 mL) of levocetirizine dihydrochloride oral solution is bioequivalent to a 5 mg dose of levocetirizine dihydrochloride tablets. Following oral administration of a 5 mg dose of levocetirizine dihydrochloride oral solution to healthy adult subjects, the mean peak plasma concentrations were achieved approximately 0.5 hour post-dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">• Distribution </span></p>
<p>The mean plasma protein binding of levocetirizine <span class="Italics">in vitro</span> ranged from 91 to 92%, independent of concentration in the range of 90 to 5000 ng/mL, which includes the therapeutic plasma levels observed. Following oral dosing, the average apparent volume of distribution is approximately 0.4 L/kg, representative of distribution in total body water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">• Metabolism</span></p>
<p>The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of hepatic drug metabolizing enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O-dealkylation, and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involves multiple and/or unidentified CYP isoforms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">• Elimination</span></p>
<p>The plasma half-life in adult healthy subjects was about 8 to 9 hours after administration of oral tablets and oral solution, and the mean oral total body clearance for levocetirizine was approximately 0.63 mL/kg/min. The major route of excretion of levocetirizine and its metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via feces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion. Renal clearance of levocetirizine correlates with that of creatinine clearance. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> the clearance of levocetirizine is reduced [see <span class="Italics"><a href="#S2.3">Dosage and Administration (2.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">• Drug Interaction Studies</span></p>
<p><span class="Italics">In vitro</span> data on metabolite interaction indicate that levocetirizine is unlikely to produce, or be subject to metabolic interactions. Levocetirizine at concentrations well above C<span class="Sub">max</span> level achieved within the therapeutic dose ranges is not an inhibitor of CYP isoenzymes 1A2, 2C9, 2C19, 2A1, 2D6, 2E1, and 3A4, and is not an inducer of UGT1A or CYP isoenzymes 1A2, 2C9 and 3A4.</p>
<p>No formal <span class="Italics">in vivo</span> drug interaction studies have been performed with levocetirizine. Studies have been performed with the racemic cetirizine [see <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">• Pediatric Patients</span></p>
<p>Data from a pediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that C<span class="Sub">max</span> and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean C<span class="Sub">max</span> was 450 ng/mL, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this pediatric population than in adults.</p>
<p>Dedicated pharmacokinetic studies have not been conducted in pediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 324 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age results in plasma concentrations similar to those of adults receiving 5 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold">• Geriatric Patients</span></p>
<p>Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65 to 74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dihydrochloride dose should be adjusted in accordance with renal function in elderly patients [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold">• Gender</span></p>
<p>Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 ± 1.72 hr) than in men (8.62 ± 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 ± 0.16 mL/min/kg) appears to be comparable to that in men (0.59 ± 0.12 mL/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Bold">• Race</span></p>
<p>The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Bold">• <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Levocetirizine exposure <span class="Bold">(</span>AUC<span class="Bold">)</span> exhibited 1.8-, 3.2-, 4.3-, and 5.7-fold increase in mild, moderate, severe, renal impaired, and end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients, respectively, compared to healthy subjects. The corresponding increases of half-life estimates were 1.4-, 2.0-, 2.9-, and 4-fold, respectively.</p>
<p>The total body clearance of levocetirizine after oral dosing was correlated to the creatinine clearance and was progressively reduced based on severity of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Therefore, it is recommended to adjust the dose and dosing intervals of levocetirizine based on creatinine clearance in patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients (CL<span class="Sub">CR</span> &lt; 10 mL/min) levocetirizine is contraindicated. The amount of levocetirizine removed during a standard 4–hour hemodialysis procedure was &lt; 10%.</p>
<p>The dosage of levocetirizine dihydrochloride should be reduced in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Both the dosage and frequency of administration should be reduced in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#S2.4">Dosage and Administration (2.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11"></a><p></p>
<p class="First"><span class="Bold">• <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Levocetirizine dihydrochloride has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The non-renal clearance (indicative of hepatic contribution) was found to constitute about 28% of the total body clearance in healthy adult subjects after oral administration.</p>
<p>As levocetirizine is mainly excreted unchanged by the kidney, it is unlikely that the clearance of levocetirizine is significantly decreased in patients with solely <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity studies have been performed with levocetirizine. However, evaluation of cetirizine carcinogenicity studies are relevant for determination of the carcinogenic potential of levocetirizine. In a 2-year carcinogenicity study, in rats, cetirizine was not carcinogenic at dietary doses up to 20 mg/kg (approximately 15 times the maximum recommended daily oral dose in adults, approximately 10 times the maximum recommended daily oral dose in children 6 to 11 years of age and approximately 15 times the maximum recommended daily oral dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2</span> basis). In a 2-year carcinogenicity study in mice, cetirizine caused an increased incidence of benign hepatic tumors in males at a dietary dose of 16 mg/kg (approximately 6 times the maximum recommended daily oral dose in adults, approximately 4 times the maximum recommended daily oral dose in children 6 to 11 years of age, and approximately 6 times the maximum recommended daily oral dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2</span> basis). No increased incidence of benign tumors was observed at a dietary dose of 4 mg/kg (approximately 2 times the maximum recommended daily oral dose in adults, equivalent to the maximum recommended daily oral dose in children 6 to 11 years of age and approximately 2 times the maximum recommended daily oral dose in children 6 months to 5 years of age on a mg/m<span class="Sup">2</span> basis). The clinical significance of these findings during long-term use of levocetirizine dihydrochloride is not known.</p>
<p>Levocetirizine was not mutagenic in the Ames test, and not clastogenic in the human lymphocyte assay, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and <span class="Italics">in vivo</span> micronucleus test in mice.</p>
<p>In a fertility and general reproductive performance study in mice, cetirizine did not impair fertility at an oral dose of 64 mg/kg (approximately 25 times the recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First">Reproductive Toxicology Studies</p>
<p>In rats and rabbits, levocetirizine was not teratogenic at oral doses up to 200 and 120 mg/kg, respectively, (approximately 320 and 390, respectively, times the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis). In mice, cetirizine caused retarded pup <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during lactation at an oral dose in dams of 96 mg/kg (approximately 40 times the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Adults and Adolescents 12 Years of Age and Older</span></p>
<p>The efficacy of levocetirizine dihydrochloride was evaluated in six randomized, placebo-controlled, double-blind clinical trials in adult and adolescent patients 12 years and older with symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>. The six clinical trials include three dose-ranging trials of 2 to 4 weeks duration, one 2-week efficacy trial in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, and two efficacy trials (one 6-week and one 6-month) in patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>.</p>
<p>These trials included a total of 2412 patients (1068 males and 1344 females) of whom 265 were adolescents 12 to 17 years of age. Efficacy was assessed using a total symptom score from patient recording of 4 symptoms (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) in five studies and 5 symptoms (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>) in one study. Patients recorded symptoms using a 0 to 3 categorical severity scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe) once daily in the evening reflective of the 24 hour treatment period. In one study, patients also recorded these symptoms in an instantaneous (1 hour before the next dose) manner. The primary endpoint was the mean total symptom score averaged over the first week and over 2 weeks for <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> trials, and 4 weeks for <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> trials.</p>
<p>The three dose-ranging trials were conducted to evaluate the efficacy of levocetirizine dihydrochloride 2.5, 5, and 10 mg once daily in the evening. One trial was 2 weeks in duration conducted in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, and two trials were 4 weeks in duration conducted in patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>. In these trials, each of the three doses of levocetirizine dihydrochloride demonstrated greater decrease in the reflective total symptom score than placebo and the difference was statistically significant for all three doses in two of the studies. Results for two of these trials are shown in Table 4.</p>
<a name="table4"></a><table width="95%">
<caption><span>Table 4 Mean Reflective Total Symptom Score<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> in <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> Dose-Ranging Trials</span></caption>
<col align="left" valign="middle" width="27%">
<col align="center" valign="middle" width="8%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Treatment</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Rrule" align="center" rowspan="2">Baseline</th>
<th class="Rrule" align="center" rowspan="2">On Treatment Adjusted Mean</th>
<th class="Rrule" align="center" colspan="3">Difference from Placebo</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Estimate</th>
<th class="Rrule" align="center">95% CI</th>
<th class="Rrule" align="center">p-value</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Total symptom score is the sum of individual symptoms of <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> as assessed by patients on a 0 to 3 categorical severity scale.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> Trial - Reflective total symptom score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 2.5 mg</td>
<td class="Rrule" align="center">116</td>
<td class="Rrule" align="center">7.83</td>
<td class="Rrule" align="center">4.27</td>
<td class="Rrule" align="center">0.91</td>
<td class="Rrule" align="center">(0.37, 1.45)</td>
<td class="Rrule" align="center">0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">115</td>
<td class="Rrule" align="center">7.45</td>
<td class="Rrule" align="center">4.06</td>
<td class="Rrule" align="center">1.11</td>
<td class="Rrule" align="center">(0.57, 1.65)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 10 mg</td>
<td class="Rrule" align="center">118</td>
<td class="Rrule" align="center">7.15</td>
<td class="Rrule" align="center">3.57</td>
<td class="Rrule" align="center">1.61</td>
<td class="Rrule" align="center">(1.07, 2.15)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">118</td>
<td class="Rrule" align="center">7.94</td>
<td class="Rrule" align="center">5.17</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> Trial – Reflective total symptom score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 2.5 mg</td>
<td class="Rrule" align="center">133</td>
<td class="Rrule" align="center">7.14</td>
<td class="Rrule" align="center">4.12</td>
<td class="Rrule" align="center">1.17</td>
<td class="Rrule" align="center">(0.71, 1.63)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">127</td>
<td class="Rrule" align="center">7.18</td>
<td class="Rrule" align="center">4.07</td>
<td class="Rrule" align="center">1.22</td>
<td class="Rrule" align="center">(0.76, 1.69)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 10 mg</td>
<td class="Rrule" align="center">129</td>
<td class="Rrule" align="center">7.58</td>
<td class="Rrule" align="center">4.19</td>
<td class="Rrule" align="center">1.10</td>
<td class="Rrule" align="center">(0.64, 1.57)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">128</td>
<td class="Rrule" align="center">7.22</td>
<td class="Rrule" align="center">5.29</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>One clinical trial was designed to evaluate the efficacy of levocetirizine dihydrochloride 5 mg once daily in the evening compared with placebo in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> over a 2-week treatment period. In this trial, levocetirizine dihydrochloride 5 mg demonstrated a greater decrease from baseline in the reflective and instantaneous total symptom score than placebo, and the difference was statistically significant (see <a href="#table5">Table 5</a>). The results of the instantaneous total symptom score support efficacy at the end of the dosing interval.</p>
<p>One clinical trial evaluated the efficacy of levocetirizine dihydrochloride 5 mg once daily in the evening compared to placebo in patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> over a 6-week treatment period. Another trial conducted over a 6-month treatment period assessed efficacy at 4 weeks. Levocetirizine dihydrochloride 5 mg demonstrated a greater decrease from baseline in the reflective total symptom score than placebo and the difference from placebo was statistically significant. Results of one of these trials are shown in Table 5.</p>
<a name="table5"></a><table width="95%">
<caption><span>Table 5 Mean Reflective Total Symptom Score<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> and Instantaneous Total Symptom Score in <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> Trials</span></caption>
<col align="left" valign="middle" width="27%">
<col align="center" valign="middle" width="8%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Treatment</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Rrule" align="center" rowspan="2">Baseline</th>
<th class="Rrule" align="center" rowspan="2">On Treatment Adjusted Mean</th>
<th class="Rrule" align="center" colspan="3">Difference from Placebo</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Estimate</th>
<th class="Rrule" align="center">95% CI</th>
<th class="Rrule" align="center">p-value</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Total symptom score is the sum of individual symptoms of <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> as assessed by patients on a 0 to 3 categorical severity scale.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> Trial - Reflective total symptom score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">118</td>
<td class="Rrule" align="center">8.40</td>
<td class="Rrule" align="center">5.20</td>
<td class="Rrule" align="center">0.89</td>
<td class="Rrule" align="center">(0.30, 1.47)</td>
<td class="Rrule" align="center">0.003</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">117</td>
<td class="Rrule" align="center">8.50</td>
<td class="Rrule" align="center">6.09</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> Trial - Instantaneous total symptom score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">118</td>
<td class="Rrule" align="center">7.24</td>
<td class="Rrule" align="center">4.58</td>
<td class="Rrule" align="center">0.73</td>
<td class="Rrule" align="center">(0.17, 1.28)</td>
<td class="Rrule" align="center">0.011</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">117</td>
<td class="Rrule" align="center">7.48</td>
<td class="Rrule" align="center">5.30</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> Trial - Reflective total symptom score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">150</td>
<td class="Rrule" align="center">7.69</td>
<td class="Rrule" align="center">3.93</td>
<td class="Rrule" align="center">1.17</td>
<td class="Rrule" align="center">(0.70, 1.64)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">142</td>
<td class="Rrule" align="center">7.44</td>
<td class="Rrule" align="center">5.10</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>Onset of action was evaluated in two environmental exposure unit studies in <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> patients with a single dose of levocetirizine dihydrochloride 2.5 or 5 mg. Levocetirizine dihydrochloride 5 mg was found to have an onset of action 1 hour after oral intake. Onset of action was also assessed from the daily recording of symptoms in the evening before dosing in the seasonal and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> trials. In these trials, onset of effect was seen after 1 day of dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients Less than 12 Years of Age</span></p>
<p>There are no clinical efficacy trials with levocetirizine dihydrochloride 2.5 mg once daily in pediatric patients under 12 years of age, and no clinical efficacy trials with levocetirizine dihydrochloride 1.25 mg once daily in pediatric patients 6 months to 5 years of age. The clinical efficacy of levocetirizine dihydrochloride in pediatric patients under 12 years of age has been extrapolated from adult clinical efficacy trials based on pharmacokinetic comparisons [see <span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Bold Italics">Adult Patients 18 Years of Age and Older</span></p>
<p>The efficacy of levocetirizine dihydrochloride for the treatment of the uncomplicated skin manifestations of chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> was evaluated in two multi-center, randomized, placebo-controlled, double-blind clinical trials of 4 weeks duration in adult patients 18 to 85 years of age with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span>. The two trials included one 4-week dose-ranging trial and one 4-week single-dose level efficacy trial. These trials included 423 patients (139 males and 284 females). Most patients (&gt; 90%) were Caucasian and the mean age was 41. Of these patients, 146 received levocetirizine dihydrochloride 5 mg once daily in the evening. Efficacy was assessed based on patient recording of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity on a severity score of 0 to 3 (0 = none to 3 = severe). The primary efficacy endpoint was the mean reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score over the first week and over the entire treatment period. Additional efficacy variables were the instantaneous <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score, the number and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span>, and duration of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>The dose-ranging trial was conducted to evaluate the efficacy of levocetirizine dihydrochloride 2.5, 5, and 10 mg once daily in the evening. In this trial, each of the three doses of levocetirizine dihydrochloride demonstrated greater decrease in the reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score than placebo and the difference was statistically significant for all three doses (see <a href="#table6">Table 6</a>). The single dose level trial evaluated the efficacy of levocetirizine dihydrochloride 5 mg once daily in the evening compared to placebo in patients with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> over a 4-week treatment period. Levocetirizine dihydrochloride 5 mg demonstrated a greater decrease from baseline in the reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score than placebo and the difference from placebo was statistically significant.</p>
<p>Duration of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, number and size of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span>, and instantaneous <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score also showed significant improvement over placebo. The significant improvement in the instantaneous <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score over placebo confirmed end of dosing interval efficacy (see <a href="#table6">Table 6</a>).</p>
<a name="table6"></a><table width="95%">
<caption><span>Table 6 Mean Reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> Severity Score in Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span> Trials</span></caption>
<col align="left" valign="middle" width="27%">
<col align="center" valign="middle" width="8%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Treatment</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Rrule" align="center" rowspan="2">Baseline</th>
<th class="Rrule" align="center" rowspan="2">On Treatment Adjusted Mean</th>
<th class="Rrule" align="center" colspan="3">Difference from Placebo</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Estimate</th>
<th class="Rrule" align="center">95% CI</th>
<th class="Rrule" align="center">p-value</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Dose-Ranging Trial – Reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 2.5 mg</td>
<td class="Rrule" align="center">69</td>
<td class="Rrule" align="center">2.08</td>
<td class="Rrule" align="center">1.02</td>
<td class="Rrule" align="center">0.82</td>
<td class="Rrule" align="center">(0.58, 1.06)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">62</td>
<td class="Rrule" align="center">2.07</td>
<td class="Rrule" align="center">0.92</td>
<td class="Rrule" align="center">0.91</td>
<td class="Rrule" align="center">(0.66, 1.16)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 10 mg</td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">2.04</td>
<td class="Rrule" align="center">0.73</td>
<td class="Rrule" align="center">1.11</td>
<td class="Rrule" align="center">(0.85, 1.37)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">60</td>
<td class="Rrule" align="center">2.25</td>
<td class="Rrule" align="center">1.84</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">Idiopathic Urticaria</span> Trial – Reflective <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> severity score</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Levocetirizine dihydrochloride 5 mg</td>
<td class="Rrule" align="center">80</td>
<td class="Rrule" align="center">2.07</td>
<td class="Rrule" align="center">0.94</td>
<td class="Rrule" align="center">0.62</td>
<td class="Rrule" align="center">(0.38, 0.86)</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">82</td>
<td class="Rrule" align="center">2.06</td>
<td class="Rrule" align="center">1.56</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients</span></p>
<p>There are no clinical efficacy trials in pediatric patients with chronic <span class="product-label-link" type="condition" conceptid="140803" conceptname="Idiopathic urticaria">idiopathic urticaria</span> [see <span class="Italics"><a href="#S8.4">Use in Specific Populations (8.4)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Levocetirizine dihydrochloride oral solution is a clear, colorless, tutti frutti flavored liquid containing 0.5 mg of levocetirizine dihydrochloride per mL and is supplied in: 2 fl oz (59 mL) bottles (NDC 51672-4161-4), 4 fl oz (118 mL) bottles (NDC 51672-4161-8), 6 fl oz (177 mL) bottles (NDC 51672-4161-5), 8 fl oz (237 mL) bottles (NDC 51672-4161-1)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20° to 25°C (68° to 77°F)</span> [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">Caution patients against engaging in hazardous occupations requiring complete mental alertness, and motor coordination such as operating machinery or driving a motor vehicle after ingestion of levocetirizine dihydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<h2>17.2 Concomitant Use of Alcohol and other Central Nervous System Depressants</h2>
<p class="First">Instruct patients to avoid concurrent use of levocetirizine dihydrochloride with alcohol or other central nervous system depressants because additional reduction in mental alertness may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<h2>17.3 Dosing of Levocetirizine dihydrochloride oral solution</h2>
<p class="First">Do not exceed the recommended daily dose in adults and adolescents 12 years of age and older of 5 mg once daily in the evening. In children 6 to 11 years of age the recommended dose is 2.5 mg once daily in the evening. In children 6 months to 5 years of age, the recommended dose is 1.25 mg once daily in the evening. Advise patients to not ingest more than the recommended dose of levocetirizine dihydrochloride because of the increased risk of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> at higher doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761<br>Dist. by: <span class="Bold">Taro Pharmaceuticals U.S.A., Inc.</span>, Hawthorne, NY 10532<br> Revised: March, 2014<br>20363-0314-1    765</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 118 mL Bottle Carton</h1>
<p class="First"><span class="Bold">One 4 fl oz<br> (118 mL) Bottle</span></p>
<p><span class="Bold">NDC 51672-4161-8</span></p>
<p><span class="Bold">Levocetirizine<br> Dihydrochloride<br> Oral Solution<br> 2.5 mg/5 mL<br> (0.5 mg/mL)</span></p>
<p><span class="Bold">Keep this and all medications<br> out of the reach of children.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">TARO</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 118 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=df2a19c7-f437-425c-8253-a2523122a653&amp;name=levocetirizine-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOCETIRIZINE DIHYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">levocetirizine dihydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51672-4161</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Levocetirizine dihydrochloride</strong> (Levocetirizine) </td>
<td class="formItem">Levocetirizine dihydrochloride</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>maltitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium acetate anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucralose</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">TUTTI FRUTTI</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51672-4161-4</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">59 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:51672-4161-8</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">118 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:51672-4161-5</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">177 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:51672-4161-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">237 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202673</td>
<td class="formItem">07/26/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Taro Pharmaceuticals U.S.A., inc.
							(145186370)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Taro Pharmaceutical Industries, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">600072078</td>
<td class="formItem">MANUFACTURE(51672-4161)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a750c178-b2c9-4575-93cd-cca0823bfd80</div>
<div>Set id: df2a19c7-f437-425c-8253-a2523122a653</div>
<div>Version: 7</div>
<div>Effective Time: 20140318</div>
</div>
</div> <div class="DistributorName">Taro Pharmaceuticals U.S.A., inc.</div></p>
</body></html>
